In summary, the first pan-cancer analysis of DYRK2 showed a statistical correlation between DYRK2 expression and clinical prognosis, DNA methylation, protein phosphorylation of clinical tumor samples, immune cell infiltration, and tumour mutation burden. This evidence concerns the gene DYRK2 and cancer.